Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Esserman

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Breast Cancer Research and Treatment|September 16, 2021
The WISDOM study: a new approach to screening can and should be testedLaura Esserman, Martin Eklund, Laura Van't Veer, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Lancet (London, England)|November 15, 2013
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialJayant S Vaidya, Frederik Wenz, Max Bulsara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Nature Biotechnology|February 5, 2025
Implantation of engineered adipocytes suppresses tumor progression in cancer modelsHai P Nguyen, Kelly An, Yusuke Ito, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Human Genetics|February 28, 2019
A response to "Personalised medicine and population health: breast and ovarian cancer"Antonis Antoniou, Hoda Anton-Culver, Alexander Borowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug developmentDouglas Yee, Tufia Haddad, Kathy Albain, et al.
Research Square|November 19, 2025
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and DesignAllison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Breast Cancer Research and Treatment|September 16, 2021
The WISDOM study: a new approach to screening can and should be testedLaura Esserman, Martin Eklund, Laura Van't Veer, et al.
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Lancet (London, England)|November 15, 2013
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trialJayant S Vaidya, Frederik Wenz, Max Bulsara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Nature Biotechnology|February 5, 2025
Implantation of engineered adipocytes suppresses tumor progression in cancer modelsHai P Nguyen, Kelly An, Yusuke Ito, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Human Genetics|February 28, 2019
A response to "Personalised medicine and population health: breast and ovarian cancer"Antonis Antoniou, Hoda Anton-Culver, Alexander Borowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug developmentDouglas Yee, Tufia Haddad, Kathy Albain, et al.
Research Square|November 19, 2025
WISDOM Randomized Trial Comparing Risk-Based Versus Annual Breast Cancer Screening: Study Cohort Characteristics and DesignAllison Fiscalini, Kelly Blum, Kirkpatrick Fergus, et al.
Pageof 15